Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Weekly News Recap #Phispers
1. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-((1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
2. Nbi 74788
3. Nbi-74788
1. Ssr 125543
2. Ssr125543
3. Ssr-125543
4. 752253-39-7
5. Nbi-74788
6. Crinecerfont [usan]
7. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
8. Mft24bx55i
9. 06-rori
10. Chembl291657
11. Chebi:34969
12. Ssr125543a
13. 752253-39-7 (free Base)
14. Chembl1628268
15. (s)-4-(2-chloro-4-methoxy-5-methylphenyl)-n-(2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-(prop-2-yn-1-yl)thiazol-2-amine
16. Sr-125543a
17. Crinecerfont [inn]
18. Unii-mft24bx55i
19. Gtpl3533
20. Schembl5453205
21. Dtxsid10996687
22. Ssr-125543a
23. Zinc1550164
24. Bdbm50144192
25. Bdbm50348828
26. Pdsp1_000883
27. Pdsp2_000869
28. Who 10958
29. Ncgc00386642-01
30. Hy-106203
31. Cs-0025238
32. Q27088874
33. [4-(4-bromo-phenyl)-5,6-dimethyl-pyrimidin-2-yl]-dicyclopropylmethyl-propyl-amine
34. 2-thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-n-((1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-2-propynyl-
35. 2-thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-2-propyn-1-yl
36. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-(prop-2-yn-1-yl)-1,3-thiazol-2-amine
Molecular Weight | 483.0 g/mol |
---|---|
Molecular Formula | C27H28ClFN2OS |
XLogP3 | 8 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 8 |
Exact Mass | 482.1594906 g/mol |
Monoisotopic Mass | 482.1594906 g/mol |
Topological Polar Surface Area | 53.6 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 699 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of atypical haemolytic uremic syndrome, Treatment of paroxysmal nocturnal haemoglobinuria
Treatment of congenital adrenal hyperplasia
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
88
PharmaCompass offers a list of Crinecerfont API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Crinecerfont manufacturer or Crinecerfont supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Crinecerfont manufacturer or Crinecerfont supplier.
PharmaCompass also assists you with knowing the Crinecerfont API Price utilized in the formulation of products. Crinecerfont API Price is not always fixed or binding as the Crinecerfont Price is obtained through a variety of data sources. The Crinecerfont Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Crinecerfont manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Crinecerfont, including repackagers and relabelers. The FDA regulates Crinecerfont manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Crinecerfont API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Crinecerfont supplier is an individual or a company that provides Crinecerfont active pharmaceutical ingredient (API) or Crinecerfont finished formulations upon request. The Crinecerfont suppliers may include Crinecerfont API manufacturers, exporters, distributors and traders.
click here to find a list of Crinecerfont suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Crinecerfont as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Crinecerfont API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Crinecerfont as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Crinecerfont and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Crinecerfont NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Crinecerfont suppliers with NDC on PharmaCompass.
Crinecerfont Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Crinecerfont GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Crinecerfont GMP manufacturer or Crinecerfont GMP API supplier for your needs.
A Crinecerfont CoA (Certificate of Analysis) is a formal document that attests to Crinecerfont's compliance with Crinecerfont specifications and serves as a tool for batch-level quality control.
Crinecerfont CoA mostly includes findings from lab analyses of a specific batch. For each Crinecerfont CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Crinecerfont may be tested according to a variety of international standards, such as European Pharmacopoeia (Crinecerfont EP), Crinecerfont JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Crinecerfont USP).